Travere Therapeutics officer plans $303K share sale
The reported sale is designated to cover tax withholding on vested performance restricted stock units, rather than as a discretionary trade.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Travere Therapeutics, Inc. officer Elizabeth E. Reed reported that 7,215 common shares are to be sold, with an aggregate market value of $302,515.98 and an approximate sale date of April 14, 2026. She acquired 7,215 shares through performance restricted stock unit vesting on April 13, 2026. Reed said the sale is mandated by the issuer’s election under its equity incentive plans to cover tax withholding through a “sell to cover” transaction with the designated broker, Morgan Stanley Smith Barney; she said it is not discretionary. The three-month sales table separately lists 37,500 common shares sold on April 14, 2026, for gross proceeds of $1,540,125.00.
Key Figures
Key Terms
Performance Restricted Stock Unit Vesting technical
sell to cover financial
tax withholding obligation financial
equity incentive plans financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
AI-generated analysis. How Rhea-AI works. Not financial advice.